{"id":588611,"date":"2022-02-28T13:12:02","date_gmt":"2022-02-28T13:12:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=588611"},"modified":"2022-02-28T13:12:02","modified_gmt":"2022-02-28T13:12:02","slug":"diabetic-peripheral-neuropathy-market-analysis-of-epidemiology-pipeline-products-and-key-companies-working-in-the-space","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/diabetic-peripheral-neuropathy-market-analysis-of-epidemiology-pipeline-products-and-key-companies-working-in-the-space_588611.html","title":{"rendered":"Diabetic Peripheral Neuropathy Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working in the Space"},"content":{"rendered":"
\n
\"Diabetic<\/a><\/div>\n
\n
Diabetic Peripheral Neuropathy market<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “Diabetic Peripheral Neuropathy Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Diabetic Peripheral Neuropathy, historical and forecasted epidemiology as well as the Diabetic Peripheral Neuropathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n

DelveInsight has launched a new report on “Diabetic Peripheral Neuropathy – Market Insights, Epidemiology, and Market Forecast-2030”.<\/a><\/strong><\/p>\n

DelveInsight’s “Diabetic Peripheral Neuropathy – Market Insights, Epidemiology, and Market Forecast-2030″<\/strong> report delivers an in-depth understanding of the Diabetic Peripheral Neuropathy, historical and forecasted epidemiology as well as the Diabetic Peripheral Neuropathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

Some of the key facts of the Diabetic Peripheral Neuropathy Market Report:<\/a><\/strong><\/p>\n

    \n
  1. According to DelveInsight estimates, the total diagnosed prevalent population of Diabetic  Peripheral Neuropathy in 7MM was found to be 25,507,330 in 2018.<\/li>\n
  2. Among the EU5 countries, Germany had the highest prevalent cases with 3,924,253   cases in 2018. <\/li>\n
  3. Among all the countries, the United States has a higher prevalent population of DPN with 12,633,933 cases in  2018.<\/li>\n
  4. Among the EU5 countries, Germany has the highest prevalent cases followed by Italy and Spain.  The UK accounted for the least number of cases for DPN in 2018<\/li>\n
  5. Japan accounted for 3,259,231 cases of Diabetic Peripheral Neuropathy in 2018.<\/li>\n<\/ol>\n

    Key benefits of the report:<\/strong><\/p>\n

      \n
    1. Diabetic Peripheral Neuropathy market report covers a descriptive overview and comprehensive insight of the Diabetic Peripheral Neuropathy Epidemiology and Diabetic Peripheral Neuropathy  market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)<\/li>\n
    2. The Diabetic Peripheral Neuropathy market report provides insights on the current and emerging therapies.<\/li>\n
    3. Diabetic Peripheral Neuropathy market report provides a global historical and forecasted market covering drug outreach in 7MM.<\/li>\n
    4. The Diabetic Peripheral Neuropathy market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Diabetic Peripheral Neuropathy market.<\/li>\n<\/ol>\n

      Got queries? Click here to know more about the Diabetic Peripheral Neuropathy Market Landscape<\/a>.<\/strong><\/p>\n

      Diabetic Peripheral Neuropathy Overview<\/strong><\/p>\n

      Diabetic peripheral neuropathy (DPN) also known Distal symmetric polyneuropathy (DSPN) is defined as the  symptoms and\/or signs of peripheral nerve dysfunction and nerve damage in diabetic patients after the exclusion of  other causes. It is a predominantly sensory neuropathy with autonomic nervous system involvement, although there  are often motor features with advancing disease.<\/p>\n

      It is a common prevalent complication in neurological damage of Type 1 and Type 2 diabetes. It is typically characterized by significant deficits in tactile sensitivity, vibration sense, lower-limb proprioception, and kinesthesia. Painful DPN has been shown to be associated with significant reductions in overall quality of life, increased levels of anxiety and depression, sleep impairment, and greater gait variability.<\/p>\n

      Diabetic Peripheral Neuropathy Market <\/strong><\/p>\n

      The dynamics of the Diabetic Peripheral Neuropathy market<\/a><\/strong> is anticipated to change in the coming years owing to the expected launch of emerging therapies such as Helixmith, WinSanTor, Regenacy Pharmaceutical, Aptinyx, Eli Lilly and Company, Lexicon Pharmaceuticals, and others during the forecasted period 2021-2030.<\/p>\n

      Learn more by requesting for sample @ Diabetic Peripheral Neuropathy Market Landscape <\/a><\/strong><\/p>\n

      Diabetic Peripheral Neuropathy Pipeline Therapies and Key Companies <\/strong><\/p>\n

        \n
      1. VM202: Helixmith<\/li>\n
      2. WST-057: WinSanTor<\/li>\n
      3. Ricolinostat: Regenacy Pharmaceutical<\/li>\n
      4. NYX-2925: Aptinyx<\/li>\n
      5. LY3016859: Eli Lilly and Company<\/li>\n
      6. LX9211: Lexicon Pharmaceuticals<\/li>\n<\/ol>\n

        Diabetic Peripheral Neuropathy Market Drivers <\/strong><\/p>\n

        1.  incidence of Diabetes<\/p>\n

        2. Advancement in early diagnosis of DPN<\/p>\n

        Table of Contents<\/strong><\/p>\n

        1. Report Introduction<\/p>\n

        2. Executive Summary<\/p>\n

        3. SWOT analysis<\/p>\n

        4. Diabetic Peripheral Neuropathy Patient Share (%) Overview at a Glance<\/p>\n

        5. Diabetic Peripheral Neuropathy Market Overview at a Glance<\/p>\n

        6. Diabetic Peripheral Neuropathy Disease Background and Overview<\/p>\n

        7. Diabetic Peripheral Neuropathy Epidemiology and Patient Population<\/p>\n

        8. Country-Specific Patient Population of Diabetic Peripheral Neuropathy <\/p>\n

        9. Diabetic Peripheral Neuropathy Current Treatment and Medical Practices<\/p>\n

        10. Unmet Needs<\/p>\n

        11. Diabetic Peripheral Neuropathy Emerging Therapies<\/p>\n

        12. Diabetic Peripheral Neuropathy Market Outlook<\/p>\n

        13. Country-Wise Diabetic Peripheral Neuropathy Market Analysis (2017–2030)<\/p>\n

        14. Market Access and Reimbursement of Therapies<\/p>\n

        15. Market drivers<\/p>\n

        16. Market barriers<\/p>\n

        17. Appendix<\/p>\n

        18. Diabetic Peripheral Neuropathy Report Methodology<\/p>\n

        19. DelveInsight Capabilities<\/p>\n

        20. Disclaimer<\/p>\n

        21. About DelveInsight<\/p>\n

        Related Reports:<\/strong><\/p>\n

        Diabetic Peripheral Neuropathy Pipeline <\/strong><\/p>\n

        Diabetic Peripheral Neuropathy Epidemiology<\/strong><\/p>\n

        Media Contact<\/span>
        Company Name:<\/strong>         DelveInsight Business Research LLP<\/a>
        Contact Person:<\/strong> Kritika Rehani
        Email:<\/strong>         Send Email<\/a>
        Phone:<\/strong> 9193216187
        Address:<\/strong>304 S. Jones Blvd #2432
        City:<\/strong> Las Vegas
        State:<\/strong> Nevada
        Country:<\/strong> United States
        Website:<\/strong>         https:\/\/www.delveinsight.com\/<\/a><\/p>\n

        <\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

        Diabetic Peripheral Neuropathy market DelveInsight’s “Diabetic Peripheral Neuropathy Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Diabetic Peripheral Neuropathy, historical and forecasted epidemiology as well as the Diabetic Peripheral Neuropathy market trends in the United … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,406,413,404],"tags":[],"class_list":["post-588611","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Services","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/588611","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=588611"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/588611\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=588611"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=588611"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=588611"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}